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Abstract BACKGROUND: HLA-G is an antigen whose participation in the regulation of the 
immune system is well documented. The aim of the present study has therefore 
been to evaluate the sHLA-G blood serum concentrations levels in both women 
with ovarian endometriosis and women with uterine leiomyomas. 
METHODS: In our study, the soluble HLA-G concentration level was evaluated in 
the blood serum samples obtained from 98 women who underwent laparotomies 
or laparoscopies due to either ovarian endometriosis or leiomyomatous uterus. 
The control group consisted of 42 women, including women on whom a diagnostic 
laparoscopy identified no lesions, and volunteers—healthy women who returned 
their blood serum samples during menstrual bleeding. 
RESULTS: Patients who underwent surgical treatment because of ovarian endo-
metriosis or uterine leiomyoma, as well as patients from the control group, 
exhibited no sHLA-G blood serum concentration level fluctuations between the 
proliferative and secretory menstrual cycle phases. The sHLA-G levels were sig-
nificantly lower in the patients with ovarian endometriosis and in the patients from 
the control group during the menstrual cycle phase than in those patients with 
leiomyoma. A similar relation between the sHLA-G levels of the postmenopausal 
patients suffering from leiomyoma and the control patients was found. In contrast, 
the postmenopausal women suffering from endometriosis were typified by levels 
of sHLA-G blood serum concentration comparable to those of the patients with 
leiomyoma, and the levels were significantly higher than those observed in the 
blood sera of the postmenopausal patients from the control group. 
CONCLUSION: The soluble HLA-G blood serum level would seem to be a useful 
marker for evaluating the status of the microenvironment, where the tumor-
immune cell and ectopic and eutopic endometrial interactions take place. 
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1. INTRODUCTION
Human leukocyte antigen–G (HLA-G), a nonclassical 
Class Ib molecule, is observed within immune cells 
and in different organs, such as the uterus, thymus, 
and placenta, among others [1–4]. Initially, HLA-G was 
found at the feto-maternal interface – specifically, on 
the extravillous cytotrophoblast in the first and third 
trimester [1]. HLA-G is an antigen whose participation 
in the regulation of the immune system has been well 
documented [4]. Moreover, HLA-G expression has been 
identified on neoplasmatic cells, including melanoma 
cells [3,5], lung cancer cells [6], neuroblastoma cells [2], 
choriocarcinoma cells [1], ovarian cancer cells [7–8], 
and others. This protein also participates in the evasion 
of immune surveillance by cancer cells [2–3]. As a class 
I histocompatibility complex (MHC), HLA-G in human 
beings is expressed in both forms---membrane–bound 
and soluble [9]. The soluble form of this protein may be 
responsible for the inhibition and even the apoptosis of 
NK cells and cytotoxic T lymphocytes [9–12]. The pres-
ence of the soluble form of HLA-G has been revealed in 
the blood sera of women during pregnancy as well as 
in the blood sera of cancer patients [2,3], patients with 
immune-mediated disorders (such as multiple sclerosis 
(MS) and rheumatoid arthritis (RA) [13–14]), and even 
healthy women [3]. In a study by Rebmann et al., the 
sHLA-G blood serum concentrations of patients with 
melanoma, ovarian cancer, and breast cancer were sig-
nificantly higher than those found in the healthy con-
trols [3]. Soluble HLA-G has moreover been found in 
the blood sera of heart-transplant patients, and it has 
been documented that sHLA-G blood serum concen-
tration correlates with better heart-graft tolerance [15]. 
The presence of sHLA-G has also been revealed in amni-
otic fluid [2], cerebral fluid [13], and peritoneal fluid 
[3,8,16]. In women with endometriosis, sHLA-G has 
been detected in peritoneal fluid [16]. Additionally, the 
presence of HLA-G positive endometrial cells has been 
revealed in peritoneal fluid during retrograde menstru-
ation [17]. The membrane-bound form of HLA-G has 
been identified in ectopic endometrial cells, in ovar-
ian endometrial lesions and, in patients with adeno-
myosis, in ectopic endometrial cells within the uterine 
wall [18,19]. Although no HLA-G expression has been 
observed in eutopic endometrium during the prolifera-
tive and secretory cycle phases, the presence of HLA-G 
positive endometrial cells has been identified during 
menstrual bleeding [17]. Furthermore, Wang et al. has 
detected HLA-G expression in eutopic endometrium 
during the different menstrual cycle phases in women 
with adenomyosis [19]. 
As a result of an alternative splicing of a primary 
HLA-G transcript, seven isoforms of the protein 
are generated. The soluble form of HLA-G can be 
either secreted (e.g., isoform HLA-G5) or proteolyti-
cally cleaved from the cell surface (isoform HLA-G1) 
[2,3,20–22]. The soluble form of this protein can be 
derived from immune cells, mainly macrophages/
monocytes [2,3,23]. Macrophages are predominant 
in immune cell infiltration into ectopic endometrium 
lesions [24–26] and into leiomyoma nodules [27], as well 
as into the menstrual endometrium [28–29]. Although 
HLA-G expression in eutopic and ectopic endometrium 
has been well documented, there is no data currently 
available on the sHLA-G blood serum concentration 
in women with endometriosis and in women with leio-
myomatous uterus. A dysfunction of macrophages has 
been observed in both endometriosis and uterine leio-
myoma, and this is significant as proper immune cell 
activity regulation is crucial for the participation of the 
endometrium in reproductive processes [30–40]. The 
aim of the present study has therefore been to evaluate 
the sHLA-G blood serum concentration levels in both 
women with ovarian endometriosis and women with 
uterine leiomyomas.
2. MATERIALS AND METHODS
2.1. Human subject
In this study, we have analyzed the blood serum samples 
obtained from 140 patients, including 50 patients with 
ovarian endometriosis, 48 suffering from leiomyomato-
sis, and 42 patients from a control group. The samples 
were classified according to the menstrual cycle phase 
in which they were collected. None of the patients 
included in our study received hormonal treatment of 
any kind. All the patients had undergone surgical treat-
ment in the Gynecology and Oncology Department of 
the Jagiellonian University, Krakow, Poland between 
January and September of 2008. The patient’s con-
sent was obtained in each case. Prior to the study, the 
approval of the Jagiellonian University Ethical Commit-
tee (KBET/135/B/2007) was also obtained. 
Ovarian endometriosis (OE)
The group of patients with ovarian endometriosis 
consisted of 50 women who had undergone laparo-
scopic procedures or laparotomies. The existence of 
endometriosis was confirmed in all cases through 
histopathological examination. Only the patients with 
advanced endometriosis were classified to this group 
(III and IV clinical stage of endometriosis according 
to the revised classification of the American Fertility 
Society from 1985). Based on the assessment of each 
patient’s level of progesterone, estradiol, and FSH in 
blood serum (Table 1), these groups were then divided 
into the following subgroups: OE-proliferative, OE-
secretory, and OE-postmenopause.
Uterine leiomyoma (UL)
The 48 patients selected for this group had undergone 
myomectomies and hysterectomies due to leiomyoma-
tosis in laparoscopic procedures or in laparotomies. 
Based on the histopathological verification of endome-
trial tissue samples and on the assessment of the levels 
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of progesterone, estradiol, and FSH in blood sera (table 
1), these 48 patients were then classified into the fol-
lowing subgroups: UL- proliferative, UL-secretory, and 
UL-postmenopause.
Control group (C)
The 42 patients in the control group were selected from 
those who had undergone laparoscopic procedures 
due to infertility and in whom fallopian tube occlu-
sion had been diagnosed as a cause of infertility. Addi-
tionally, healthy female volunteers who returned their 
blood serum samples during menstrual bleeding were 
included in this group. The volunteers had normal, reg-
ular menstrual periods, and gynecological and vaginal 
ultrasound examinations before and after their men-
strual periods revealed no pathological lesions within 
the reproductive tract. According to the level of proges-
terone, estradiol, and FSH in the blood serum (Table 
1) of each patient, the group was then divided into 
the following subgroups: C-proliferative, C-secretory, 
C-menstruation, and C-postmenopause.
2.2. ELISA
The blood was collected in a serum collection tube prior 
to surgery in patients who were undergoing laparoscopy 
or laparotomy, and during menstrual bleeding from the 
C-menstruation patient group. A clot was allowed to 
form at room temperature for 30–60 minutes. The tube 
was then placed on ice for 30 minutes in order to con-
tract the clot. After this, the serum samples were cen-
trifuged at 3000xg for 10 minutes at room temperature. 
The supernatants 1.0–2.0 ml were collected and stored 
at –80°C. The soluble human leukocyte antigen-G 
(sHLA-G) was detected using the sHLA-G sandwich 
ELISA kit (BioVendor-Exibo, Czech Republic). Briefly 
stated, the blood plasma samples were diluted twice 
and incubated for 1 hour in the 96-well microplate 
precoated with the monoclonal anti-sHLA-G antibod-
ies. Following incubation, the wells were washed and 
then filled with the monoclonal anti-human beta-2
-microglobulin antibodies labeled with horseradish 
peroxidase. After an additional 1 hour of incubation, 
the wells were again washed, and the color reaction was 
developed using tetramethyl benzidine (TMB) sub-
strate. The absorbance values were measured at 450 nm 
on a microplate reader followed by calculation of the 
sHLA-G concentrations. The assay was calibrated using 
a set of sHLA-G standards provided by the producer of 
the kit.
2.3. Statistical analysis
The distribution of variables in the study groups of 
women checked with the use of the Shapiro-Wilk test 
showed that each of them was different from normal. 
The statistical significance between the groups was 
determined by the Kruskal-Wallis analysis of variance 
(ANOVA) test. The Mann-Whitney U test was then 
used as applicable.
3. RESULTS
The sHLA-G blood serum concentration levels were 
assessed in the blood sera obtained from women oper-
ated on due to either uterine leiomyoma or ovarian 
endometriosis during the proliferative and secretory 
cycle phases. In the control group consisting of healthy 
women, the blood serum concentration levels were 
determined in the proliferative and secretory cycle 
phases as well as during menstrual bleeding. Addition-
ally, the sHLA-G blood serum concentration levels were 
determined for the postmenopausal patients in each of 
the examined groups.
The highest levels of blood serum HLA-G concen-
tration were found in the patients suffering from leio-
myoma during the secretory and proliferative cycle 
phases, while the lowest sHLA-G levels were observed 
in the healthy women at the time of menstruation. 
Patients who underwent surgical treatment because of 
ovarian endometriosis and uterine leiomyoma, as well 
as the patients from the control group, exhibited no 
sHLA-G blood serum concentration level fluctuation 
between the proliferative and secretory cycle phases 
(Figures 1÷3). 
Table 1. Clinical characteristics of patients classified into subgroups 
in regarding to menstrual cycle phases and after menopause. The 
data is presented as a mean and standard deviation (±SD).
Proliferative
cycle phase
Secretory
cycle phase
Postmenopausal 
women
Uterine 
leiomyoma 
(UL)
(n=48)
Age
(years)
37.5
(±8.6)
40.8
(±6.2)
55.2
(±8.4)
FSH
(mIU/ml)
5.93
(±1.73)
5.3
 (±3.9)
61.7
 (±22.3)
Estradiol
(pg/ml)
181.5
(±119.02)
110.6
(±33.8)
17.6
(±9.08)
Progesteron
(ng/ml)
0.49
(±0.22)
8.26
(± 3.87)
0.32
(±0.3)
Age
(years)
38.4
 (±8.6)
35.2
 (±6.1)
58.1
 (±8.8)
Ovarian 
endometriosis 
(OE)
(n=50)
FSH
(mIU/ml)
7.14
(±5.26)
5.17
(±2.14)
65.2
(±19.4)
Estradiol
(pg/ml)
116.3
(±122.9)
114.6
(± 62.6)
32.7
(±36.03)
Progesteron
(ng/ml)
0.95
(±0.79)
7.4
(±6.4)
0.49
(±0.23)
Age
(years)
31.3
 (±2.12)
30.5
 (±3.2)
60.0
 (±6.6)
Control group 
(C)
(n=42)
FSH
(mIU/ml)
5.45
(±.76)
5.97
(±4.43)
99.1
(±46.1)
Estradiol
(pg/ml)
278.13
(±220.3)
118.8
(±42.11)
18.6
(±16.5)
Progesteron
(ng/ml)
1.03
(±0.49)
7.32
(±3.62)
0.33
(±0.2)
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from the control group in adequate menstrual cycle 
phase (CMenstrualCycle – CMC).
 Significant differences in sHLA-G blood serum con-
centration levels were observed between the patients in 
the different menstrual cycle phases and the postmeno-
pausal patients suffering from leiomyoma as well as 
those derived from the control group. No such differ-
ences, however, were observed in the patients suffering 
from ovarian endometriosis (Table 2).
Figure 1. sHLA-G blood serum 
concentration levels during 
the menstrual cycle phases 
in patients operated on due 
to uterine leiomyoma (UL). 
Based on the histopathological 
verification of endometrial 
tissue samples and on the 
assessment of the levels 
of progesterone, estradiol, 
and FSH in blood sera, these 
patients were then classified 
into the following subgroups: 
UL- proliferative, UL-secretory, 
and UL-postmenopause.
Figure 2. sHLA-G blood serum 
concentration levels during 
the menstrual cycle phases in 
patients operated on due to 
ovarian endometriosis (OE). 
Based on the assessment 
of each patient’s level of 
progesterone, estradiol, and 
FSH in blood serum, these 
groups were then divided into 
the f    ollowing subgroups: OE- 
proliferative, OE-secretory, and 
OE-postmenopause.
Fig. 1. 
Fig. 2. 
Since the blood serum concentration levels of 
sHLA-G in women with either leiomyoma or endo-
metriosis as well as in the control group did not appear 
to fluctuate between the proliferative and secretory 
cycle phases, in further analyses we put together indi-
viduals from the proliferative and secretory subgroups 
into new subgroups named according to the particular 
menstrual cycle phase as follows: patients with endo-
metriosis (OEMenstrualCycle – OEMC), patients with 
leiomyoma (ULMenstrualCycle – ULMC), and patients 
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The sHLA-G levels were significantly lower in the 
patients with ovarian endometriosis and in the patients 
from the control group in comparison to the levels 
found in the blood sera of the patients with leiomyoma 
(respectively ULMC vs OEMC, p= 0.057; ULMC vs 
CMC, p= 0.01;). No such differences between sHLA-G 
levels were observed, however, in the blood sera of the 
patients with endometriosis when compared with the 
control patients in the menstrual cycle phase (OEMC 
vs CMC, p= 0.4). A similar relation in the sHLA-G 
levels was found to exist between the postmenopausal 
patients suffering from leiomyoma and the control 
patients (ULM vs CM, p= 0.09). In contrast, the post-
menopausal women suffering from endometriosis were 
typified by levels of sHLA-G blood serum concentra-
tion that were comparable to those of the patients 
with leiomyoma (OEM vs ULM, p= 0.8). The levels of 
sHLA-G found in the patients with endometriosis were 
statistically significantly higher than those observed in 
the blood sera of the postmenopausal patients from the 
control group (OEM vs CM, p= 0.04)
4. DISCUSSION
In our study, the sHLA-G levels were significantly 
lower in patients with ovarian endometriosis and in the 
patients from the control group in the menstrual cycle 
phase than in the patients with leiomyoma. A similar 
relation between the sHLA-G levels of the postmeno-
pausal patients suffering from leiomyoma and the con-
trol patients was found. In contrast, the postmenopausal 
women suffering from endometriosis were typified by 
levels of sHLA-G blood serum concentration compa-
rable to those of the patients with leiomyoma, and the 
levels were significantly higher than those observed in 
the blood sera of the postmenopausal patients from the 
control group. 
To our knowledge, this is the first investigation to 
focus on the sHLA-G blood serum levels in both women 
with endometriosis and women with leiomyoma and to 
be carried out not only in accordance with the men-
strual cycle phases, but also with regard to menopause. 
The presence of sHLA-G in the PF of women with 
Fig. 3. 
Table 2. Analysis of sHLA-G serum concentration level (U/ml) in accordance with hormonal status in patients 
with uterine leiomyoma (UL) and ovarian endometriosis (OE) as well as in patients from the control group (C). 
sHLA-G blood serum concentration (U/ml)
(median, IQR)
Patients in menstrual cycle phase Postmenopausal patients p-value
Uterine leiomyoma (UL)
(n=48)
9.01
(20.6)
4.73
(4.01)
0.04
Ovarian endometriosis (OE)
(n=50)
3.98
(7.6)
3.58
(3.4)
0.2
Control group (C)
(n=42)
3.31
(9.6)
1.28
(0.71)
0.04
IQR – intraquartile range
Figure 3. sHLA-G blood 
serum concentration levels 
during the menstrual cycle 
phases in patients from 
the control group (C). 
According to the level of 
progesterone, estradiol, 
and FSH in the blood serum 
of each patient, the group 
was then divided into the 
following subgroups: C- 
proliferative, C-secretory, 
C-menstruation, and 
C-postmenopause.
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endometriosis has recently been discovered, but no 
differences in the sHLA-G concentration levels in the 
PF between the women with endometriosis and the 
healthy women were observed [16]. Rebmann et al. has 
found sHLA-G in the blood sera of healthy women, and 
the level was comparable to the level of sHLA-G in the 
blood serum identified in our study [3]. 
The membrane-bound form of HLA-G has been 
detected in the eutopic endometrial cells of women 
with endometriosis or leiomyoma only during men-
strual bleeding [17]. Furthermore, no HLA-G expres-
sion has been identified in the eutopic endometrium 
of these patients during the proliferative and secretory 
cycle phases [17,18]. It should be noted, however, that 
in this particular study, the authors did not examine 
postmenopausal patients. Meanwhile, Barrier et al. has 
demonstrated that HLA-G protein is usually expressed 
in the glandular epithelium of ectopic endometrial 
lesions and is rarely expressed in stromal cells [18]. 
Additionally, he demonstrated the presence of HLA-G 
in endometrial cells in the PF in women both with 
and without endometriosis [18]. Kawashima et al. has 
detected the HLA-G protein in endometrial cells in 
the PF during retrograde menstruation [17], while, by 
contrast, Hornung et al. observed no HLA-G expres-
sion in an endometrial cell culture derived from the 
PF of women with endometriosis [41]. The latter result 
is most likely linked to the use in this study of West-
ern blot methodology to detect sHLA-G expression 
without the concomitant ability to distinguish stroma 
from glandular epithelium [18]. More recently, Wang 
et al. observed a significantly higher level of HLA-G 
expression in ectopic endometrium compared to those 
levels found in eutopic endometrium during the pro-
liferative and secretory cycle phases in women with 
adenomyosis [19]. Moreover, no such expression was 
observed in women with leiomyoma [19]. The authors 
have consequently suggested that endometrial HLA-G 
expression may result from the presence of inflamma-
tion within the endometrium. Such inflammation is a 
response to immune cell activity and the secretion of 
various cytokines into the microenvironment of the 
endometrium [19]. Urosevic et al. has identified a cor-
relation between IL-10 and HLA-G expression in the 
lung cancer nest [6], while Moreau et al. has demon-
strated that IL-10 may up-regulate HLA-G expression 
in peripheral blood monocytes [42]. Additionally, the 
latter study found that IL-10 up-regulates the expres-
sion of HLA-G in trophoblast cells [42]. Certainly at 
the maternal-fetal interface the soluble form of HLA-G 
may derive from macrophages in response to INF-
gama stimulation [23,43]. Although the soluble form of 
HLA-G does chiefly derive from macrophages [3,23], 
lymphocyte T CD4+ may also be a source of sHLA-G 
[15]. After all, HLA-G is an antigen whose participation 
in the regulation of the immune system has been well 
documented [2–4], and soluble HLA-G is responsible 
for the inhibition and apoptosis of CTLs and NK cells 
[9–12]. Lindaman et al. has shown both that sHLA-G in 
dose-dependent manner inhibits the cytolitic activity of 
NK cells and that the increase in sHLA-G concentration 
seen in in vitro culture is associated in a concentration-
dependent manner with an increase in the apoptosis of 
NK cells. Finally, Lindaman has posited that sHLA-G 
abrogates NK cells [9]. 
The microenvironment of the endometrium is 
where the interaction of endometrial and immune 
cells takes place during reproductive processes. The 
proper activity of immune cells (such as dNK cells, 
macrophages, and others infiltrating endometrium) 
regulated by endometrial cells is necessary not only for 
successful implantation, but also for the cessation of the 
molecular changes that take place during menstrua-
tion, beginning with decidualization. These processes 
are more prominent during menstrual bleeding than 
during the different cycle phases. During menstruation 
the endometrium is infiltrated not so much by dNK 
cells (such as has been observed in the secretory cycle 
phase [44]) as by a subsequent increase in the number 
of neutrophils and macrophages [28–29]. The increas-
ing number of macrophages associated with HLA-G 
expression in endometrial cells and with the presence 
of inflammation in the endometrial microenvironment 
during menstruation results in a low level of sHLA-G 
in the blood sera, most likely from the emergence of 
menstrual lochia and the start of menstrual bleeding, 
as the menstrual lochia contain HLA-G positive cells 
[17] and probably soluble isoforms of this protein. In 
our study, the blood serum sHLA-G concentration level 
was lowest during menstrual bleeding and, moreover, 
this value was significantly lower than that found in 
any of the different menstrual cycle phases. Retrograde 
menstruation enables the dissemination of endometrial 
cells within the peritoneal cavity and – if the ectopic 
endometrial cells can escape immune system surveil-
lance – the subsequent development of endometriosis 
(The escape of ectopic endometrial cells from immune 
system surveillance is currently under study). As in the 
cancer microenvironment, macrophages seem to play 
a dual role in this phenomenon [45–49]. On the one 
hand, macrophages infiltrating an endometriosis lesion 
may participate in the rejection of tumor cells, but on 
the other hand, may actually assist in tumor-immune 
system counterattack. Pistoia et al. has demonstrated 
that monocytes in the neuroblastoma microenviron-
ment may secrete sHLA-G in response to activation by 
cytokines (IL-10 among others) deriving from tumor 
cells [2]. An increased infiltration of endometrio-
sis lesions by macrophages has been identified in the 
peritoneal lesions of early, active endometriosis [25]. 
Moreover, women with endometriosis are typified 
by an increase in monocyte activity in the peripheral 
blood, and the ability of these cells to increase the secre-
tion of IL-10 has been documented [24]. Furthermore, 
sHLA-G inhibits NK cells and cytotoxic lymphocytes, 
which in turn protect tumors from the immune system 
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[2]. The increasing concentration of sHLA-G in the 
blood sera of patients with various neoplasms reduces 
immune surveillance, thus favoring the progression 
of cancer [3]. This provides a plausible explanation 
for the higher concentration levels of sHLA-G in the 
postmenopausal patients with endometriosis in com-
parison to the control group. As in cases of patients 
with leiomyoma, the higher concentration levels may 
be linked to macrophage dysfunction. Miura et al. has 
demonstrated that myoma nodules, myometrium, and 
endometrium are all widely infiltrated by macrophages 
[27]. Moreover, both the increase in macrophage 
activity in the peritoneal fluid [46], and the increase 
in cytokine concentration linked with inflammatory 
processes within the endometrium have been observed 
in women with uterine leiomyoma [27]. The degree 
of macrophage infiltration within the endometrium, 
myometrium, and myoma nodules did not differ in the 
subsequent menstrual cycle phases and, furthermore, 
was independent of the presence of associated endome-
triosis lesions [27]. In our study, no differences were 
found between the sHLA-G levels in the secretory and 
proliferative cycle phases of patients with endometrio-
sis or of patients with leiomyoma. Additionally, Mira et 
al. has shown that GnRH analogue therapy in women 
with leiomyoma results in a decrease in macrophage 
infiltration into the endometrium, myometrium, and 
myoma nodules [27]. GnRH analogue therapy brings 
about a hormonal status in the patient comparable to 
that observed in postmenopausal patients. In our study, 
we have seen significantly lower sHLA-G levels in post-
menopausal patients in comparison to the levels found 
in women during the various menstrual cycle phases.
In sum, sHLA-G molecules participate in the regu-
lation of the immune response in the endometrium 
microenvironment during pregnancy [1–4,9–12]. The 
blood serum concentration level of sHLA-G increases 
in pathological conditions – such as tumors and 
immune-mediated disorders – in which the dysfunc-
tion of immune cells has been observed, as it has in 
the blood sera of women with endometriosis and leio-
myoma in our study. The sHLA-G concentration level 
would thus appear to provide important information 
about disturbances in the immune system associated 
with this pathological condition.
5. CONCLUSIONS
Overall, the soluble HLA-G blood serum level would 
seem to be a useful marker for evaluating the status of 
the microenvironment, where the tumor-immune cell 
and ectopic and eutopic endometrial interactions take 
place. 
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